4/23
08:09 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.
4/9
08:25 am
atxs
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]
Low
Report
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]
4/9
08:00 am
atxs
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
Low
Report
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
4/3
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
09:33 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
High
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
3/26
08:13 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $27.00. They now have a "buy" rating on the stock.
High
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $27.00. They now have a "buy" rating on the stock.
3/25
01:01 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/25
07:45 am
atxs
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE [Yahoo! Finance]
3/25
07:30 am
atxs
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Medium
Report
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
3/23
11:05 am
atxs
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company [Yahoo! Finance]
Low
Report
Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company [Yahoo! Finance]
3/18
03:10 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/5
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/5
09:11 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
3/5
08:14 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/4
04:22 pm
atxs
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Low
Report
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update [Yahoo! Finance]
3/4
04:10 pm
atxs
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Low
Report
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
2/20
08:12 am
atxs
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
2/20
08:00 am
atxs
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
Low
Report
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
2/9
06:46 pm
atxs
Green Plains, Tilly's See Activist Investor Action [MarketWatch]
Low
Report
Green Plains, Tilly's See Activist Investor Action [MarketWatch]
2/6
08:19 am
atxs
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/6
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
Low
Report
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/5
04:00 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
04:40 am
atxs
Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout [Seeking Alpha]
Medium
Report
Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout [Seeking Alpha]
1/30
07:52 pm
atxs
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc [Yahoo! Finance]
Medium
Report
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc [Yahoo! Finance]
1/30
11:20 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.